Cboe UK CHF

Medartis Holding AG (MEDZ.XC)

Compare
65.00
-2.60
(-3.85%)
At close: 4:00:37 PM GMT
Loading Chart for MEDZ.XC
DELL
  • Previous Close 67.60
  • Open 65.00
  • Bid 64.10 x --
  • Ask --
  • Day's Range 65.00 - 65.00
  • 52 Week Range 45.50 - 90.00
  • Volume 7
  • Avg. Volume 111
  • Market Cap (intraday) 883.708M
  • Beta (5Y Monthly) 0.95
  • PE Ratio (TTM) 209.68
  • EPS (TTM) 0.31
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. The company offers osteosynthesis instruments for the areas of the hand, wrist, forearm, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names. It serves the surgeons, hospitals, and medical centers, as well as group purchasing organizations. The company was incorporated in 1997 and is headquartered in Basel, Switzerland.

www.medartis.com

860

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MEDZ.XC

View More

Performance Overview: MEDZ.XC

Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

MEDZ.XC
14.84%
MSCI WORLD
0.28%

1-Year Return

MEDZ.XC
15.58%
MSCI WORLD
0.00%

3-Year Return

MEDZ.XC
46.46%
MSCI WORLD
17.52%

5-Year Return

MEDZ.XC
46.46%
MSCI WORLD
56.13%

Compare To: MEDZ.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MEDZ.XC

View More

Valuation Measures

Annual
As of 1/14/2025
  • Market Cap

    910.90M

  • Enterprise Value

    904.76M

  • Trailing P/E

    218.06

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.97

  • Price/Book (mrq)

    3.37

  • Enterprise Value/Revenue

    4.11

  • Enterprise Value/EBITDA

    31.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.83%

  • Return on Assets (ttm)

    1.84%

  • Return on Equity (ttm)

    1.50%

  • Revenue (ttm)

    220.28M

  • Net Income Avi to Common (ttm)

    4.03M

  • Diluted EPS (ttm)

    0.31

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    127.09M

  • Total Debt/Equity (mrq)

    44.37%

  • Levered Free Cash Flow (ttm)

    20.47M

Research Analysis: MEDZ.XC

View More

Company Insights: MEDZ.XC

Research Reports: MEDZ.XC

View More